We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bioniche Granted Patent for Oligonucleotide Technology
News

Bioniche Granted Patent for Oligonucleotide Technology

Bioniche Granted Patent for Oligonucleotide Technology
News

Bioniche Granted Patent for Oligonucleotide Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bioniche Granted Patent for Oligonucleotide Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bioniche Life Sciences Inc. has announced that it has been granted a European patent - EP1432450 - covering the composition and use of an oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides", inventors Dr. Nigel C. Phillips, Dr. Mario C. Filion, and Dr. Andrea Herrera-Gayol.

Dr. Nigel C. Phillips, Chief Scientific Officer for Bioniche Life Sciences Inc. stated, "This patent consolidates our oligonucleotide patent portfolio. These oligonucleotides constitute a new composition family that enhances our ability to develop effective treatments for oncology indications."

"Bioniche now has technology platforms based on mycobacterial cell walls, unmodified oligonucleotides and modified oligonucleotides that have immune stimulant and anticancer activity."

"Bioniche is in a position to develop effective treatments for cancer using these unique and complementary technology platforms."

Graeme McRae, President & CEO of Bioniche Life Sciences Inc., commented, "The oligonucleotide platform is another example of Bioniche's ability to develop novel technologies."

"We plan to develop this platform through additional pre-clinical research in the immunomodulatory and anti-cancer areas and seek opportunities to partner the technology for further development."

Advertisement